Furthermore, recent evidence suggests that, in addition to conventional blood pressure management with renin-angiotensin system inhibitors and calcium channel blockers, SGLT2 inhibitors may be beneficial as prevention for the recurrence of atrial fibrillation after catheter ablation for CKD [30]. The gene discussed is SLC5A2; the disease is atrial fibrillation.